Equities research analysts expect Lineage Cell Therapeutics (NASDAQ:LCTX) to report ($0.05) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Lineage Cell Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Lineage Cell Therapeutics reported earnings per share of ($0.07) during the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The firm is scheduled to issue its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Lineage Cell Therapeutics will report full-year earnings of ($0.06) per share for the current fiscal year, with EPS estimates ranging from ($0.10) to $0.00. For the next financial year, analysts forecast that the business will report earnings of ($0.25) per share, with EPS estimates ranging from ($0.36) to ($0.14). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Lineage Cell Therapeutics.
Lineage Cell Therapeutics (NASDAQ:LCTX) last posted its earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.78 million for the quarter, compared to the consensus estimate of $1.04 million.
NASDAQ:LCTX traded up $0.01 on Tuesday, hitting $0.94. The stock had a trading volume of 1,903 shares, compared to its average volume of 660,860. The stock has a fifty day moving average price of $0.97. Lineage Cell Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.28.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Featured Article: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.